US FDA approves Baraclude label update
This article was originally published in Scrip
Executive Summary
The US FDA has approved an update to the label for Bristol-Myers Squibb's Baraclude (entecavir) to include data on African Americans and liver transplant recipients with chronic hepatitis B infection.